Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2000 Jul 3;83(3):338–345. doi: 10.1054/bjoc.2000.1273

Characterization and modulation of drug resistance of human paediatric rhabdomyosarcoma cell lines

H A Cocker 1, C R Pinkerton 2, L R Kelland 1
PMCID: PMC2374566  PMID: 10917549

Abstract

The role of multidrug resistance (MDR) and p53 functional status in the treatment of paediatric rhabdomyosarcoma is unclear. We have characterized a panel of seven human rhabdomyosarcoma cell lines for MDR and p53 phenotype. None of the cell lines had P-glycoprotein (P-gp) or multidrug resistance-related protein (MRP) detectable by Western blotting, whereas immunohistochemistry suggested that very low levels of MDR proteins may be present in some of the lines. RT-PCR studies indicated that mdr-1, mrp-1 and lrp mRNA was present in 5/7, 7/7 and 5/7 lines respectively. The function of p53 is compromised in six of the lines, either through mutation of the p53 gene or by overexpression of mdm-2. The sensitivity of many of the cell lines to vincristine could be modulated above 2-fold and as high as 16-fold using two modulating agents, PSC833 and VX710 (with VX710 being a significantly more potent modulator of the rhabdomyosarcoma lines). PSC833 also increased vincristine accumulation in all of the lines from 1.2- to 2.2-fold. These results suggest that some of these cell lines have low levels of multidrug resistance. The level of MDR proteins is very low and therefore difficult to detect, but may be sufficient to confer low-level, but clinically relevant, resistance to some cytotoxic agents, especially vincristine. These cell lines will therefore provide a suitable model to test new strategies in treatment and for further understanding relationships between protein expression and drug resistance. © 2000 Cancer Research Campaign

Keywords: rhabdomyosarcoma, MDR-1, resistance, modulation

Full Text

The Full Text of this article is available as a PDF (260.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barrand M. A., Heppell-Parton A. C., Wright K. A., Rabbitts P. H., Twentyman P. R. A 190-kilodalton protein overexpressed in non-P-glycoprotein-containing multidrug-resistant cells and its relationship to the MRP gene. J Natl Cancer Inst. 1994 Jan 19;86(2):110–117. doi: 10.1093/jnci/86.2.110. [DOI] [PubMed] [Google Scholar]
  2. Bordow S. B., Haber M., Madafiglio J., Cheung B., Marshall G. M., Norris M. D. Expression of the multidrug resistance-associated protein (MRP) gene correlates with amplification and overexpression of the N-myc oncogene in childhood neuroblastoma. Cancer Res. 1994 Oct 1;54(19):5036–5040. [PubMed] [Google Scholar]
  3. Chan H. S., Thorner P. S., Haddad G., Ling V. Immunohistochemical detection of P-glycoprotein: prognostic correlation in soft tissue sarcoma of childhood. J Clin Oncol. 1990 Apr;8(4):689–704. doi: 10.1200/JCO.1990.8.4.689. [DOI] [PubMed] [Google Scholar]
  4. Chaudhary P. M., Roninson I. B. Induction of multidrug resistance in human cells by transient exposure to different chemotherapeutic drugs. J Natl Cancer Inst. 1993 Apr 21;85(8):632–639. doi: 10.1093/jnci/85.8.632. [DOI] [PubMed] [Google Scholar]
  5. Cole S. P., Bhardwaj G., Gerlach J. H., Mackie J. E., Grant C. E., Almquist K. C., Stewart A. J., Kurz E. U., Duncan A. M., Deeley R. G. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science. 1992 Dec 4;258(5088):1650–1654. doi: 10.1126/science.1360704. [DOI] [PubMed] [Google Scholar]
  6. Cowie F. J., Pinkerton C. R., Phillips M., Dick G., Judson I., McCarthy P. T., Flanagan R. J. Continuous-infusion verapamil with etoposide in relapsed or resistant paediatric cancers. Br J Cancer. 1995 Apr;71(4):877–881. doi: 10.1038/bjc.1995.169. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Cowie F. J., Pritchard-Jones K., Renshaw J., Pinkerton C. R. Multidrug resistance modulation in rhabdomyosarcoma and neuroblastoma cell lines. Int J Oncol. 1998 May;12(5):1143–1149. doi: 10.3892/ijo.12.5.1143. [DOI] [PubMed] [Google Scholar]
  8. Douglass E. C., Valentine M., Etcubanas E., Parham D., Webber B. L., Houghton P. J., Houghton J. A., Green A. A. A specific chromosomal abnormality in rhabdomyosarcoma. Cytogenet Cell Genet. 1987;45(3-4):148–155. doi: 10.1159/000132446. [DOI] [PubMed] [Google Scholar]
  9. Felix C. A., Kappel C. C., Mitsudomi T., Nau M. M., Tsokos M., Crouch G. D., Nisen P. D., Winick N. J., Helman L. J. Frequency and diversity of p53 mutations in childhood rhabdomyosarcoma. Cancer Res. 1992 Apr 15;52(8):2243–2247. [PubMed] [Google Scholar]
  10. Ford J. M. Experimental reversal of P-glycoprotein-mediated multidrug resistance by pharmacological chemosensitisers. Eur J Cancer. 1996 Jun;32A(6):991–1001. doi: 10.1016/0959-8049(96)00047-0. [DOI] [PubMed] [Google Scholar]
  11. Garvin A. J., Stanley W. S., Bennett D. D., Sullivan J. L., Sens D. A. The in vitro growth, heterotransplantation, and differentiation of a human rhabdomyosarcoma cell line. Am J Pathol. 1986 Oct;125(1):208–217. [PMC free article] [PubMed] [Google Scholar]
  12. Germann U. A., Ford P. J., Shlyakhter D., Mason V. S., Harding M. W. Chemosensitization and drug accumulation effects of VX-710, verapamil, cyclosporin A, MS-209 and GF120918 in multidrug resistant HL60/ADR cells expressing the multidrug resistance-associated protein MRP. Anticancer Drugs. 1997 Feb;8(2):141–155. doi: 10.1097/00001813-199702000-00005. [DOI] [PubMed] [Google Scholar]
  13. Germann U. A., Shlyakhter D., Mason V. S., Zelle R. E., Duffy J. P., Galullo V., Armistead D. M., Saunders J. O., Boger J., Harding M. W. Cellular and biochemical characterization of VX-710 as a chemosensitizer: reversal of P-glycoprotein-mediated multidrug resistance in vitro. Anticancer Drugs. 1997 Feb;8(2):125–140. doi: 10.1097/00001813-199702000-00004. [DOI] [PubMed] [Google Scholar]
  14. Hayashi Y., Sugimoto T., Horii Y., Hosoi H., Inazawa J., Kemshead J. T., Inaba T., Hanada R., Yamamoto K., Gown A. M. Characterization of an embryonal rhabdomyosarcoma cell line showing amplification and over-expression of the N-myc oncogene. Int J Cancer. 1990 Apr 15;45(4):705–711. doi: 10.1002/ijc.2910450423. [DOI] [PubMed] [Google Scholar]
  15. Houghton J. A., Houghton P. J., Webber B. L. Growth and characterization of childhood rhabdomyosarcomas as xenografts. J Natl Cancer Inst. 1982 Mar;68(3):437–443. [PubMed] [Google Scholar]
  16. Keleti J., Quezado M. M., Abaza M. M., Raffeld M., Tsokos M. The MDM2 oncoprotein is overexpressed in rhabdomyosarcoma cell lines and stabilizes wild-type p53 protein. Am J Pathol. 1996 Jul;149(1):143–151. [PMC free article] [PubMed] [Google Scholar]
  17. Kelland L. R., Bingle L., Edwards S., Steel G. G. High intrinsic radiosensitivity of a newly established and characterised human embryonal rhabdomyosarcoma cell line. Br J Cancer. 1989 Feb;59(2):160–164. doi: 10.1038/bjc.1989.34. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Kondo S., Kondo Y., Hara H., Kaakaji R., Peterson J. W., Morimura T., Takeuchi J., Barnett G. H. mdm2 gene mediates the expression of mdr1 gene and P-glycoprotein in a human glioblastoma cell line. Br J Cancer. 1996 Oct;74(8):1263–1268. doi: 10.1038/bjc.1996.527. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Kuttesch J. F., Parham D. M., Luo X., Meyer W. H., Bowman L., Shapiro D. N., Pappo A. S., Crist W. M., Beck W. T., Houghton P. J. P-glycoprotein expression at diagnosis may not be a primary mechanism of therapeutic failure in childhood rhabdomyosarcoma. J Clin Oncol. 1996 Mar;14(3):886–900. doi: 10.1200/JCO.1996.14.3.886. [DOI] [PubMed] [Google Scholar]
  20. LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
  21. Lane D. P. Cancer. p53, guardian of the genome. Nature. 1992 Jul 2;358(6381):15–16. doi: 10.1038/358015a0. [DOI] [PubMed] [Google Scholar]
  22. McAllister R. M., Melnyk J., Finkelstein J. Z., Adams E. C., Jr, Gardner M. B. Cultivation in vitro of cells derived from a human rhabdomyosarcoma. Cancer. 1969 Sep;24(3):520–526. doi: 10.1002/1097-0142(196909)24:3<520::aid-cncr2820240313>3.0.co;2-m. [DOI] [PubMed] [Google Scholar]
  23. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983 Dec 16;65(1-2):55–63. doi: 10.1016/0022-1759(83)90303-4. [DOI] [PubMed] [Google Scholar]
  24. Naito M., Tsuruo T. New multidrug-resistance-reversing drugs, MS-209 and SDZ PSC 833. Cancer Chemother Pharmacol. 1997;40 (Suppl):S20–S24. doi: 10.1007/s002800051056. [DOI] [PubMed] [Google Scholar]
  25. O'Connor P. M., Jackman J., Bae I., Myers T. G., Fan S., Mutoh M., Scudiero D. A., Monks A., Sausville E. A., Weinstein J. N. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res. 1997 Oct 1;57(19):4285–4300. [PubMed] [Google Scholar]
  26. Pappo A. S., Shapiro D. N., Crist W. M., Maurer H. M. Biology and therapy of pediatric rhabdomyosarcoma. J Clin Oncol. 1995 Aug;13(8):2123–2139. doi: 10.1200/JCO.1995.13.8.2123. [DOI] [PubMed] [Google Scholar]
  27. Pestell K. E., Medlow C. J., Titley J. C., Kelland L. R., Walton M. I. Characterisation of the p53 status, BCL-2 expression and radiation and platinum drug sensitivity of a panel of human ovarian cancer cell lines. Int J Cancer. 1998 Sep 11;77(6):913–918. doi: 10.1002/(sici)1097-0215(19980911)77:6<913::aid-ijc19>3.0.co;2-1. [DOI] [PubMed] [Google Scholar]
  28. Pinkerton C. R. Multidrug resistance reversal in childhood malignancies--potential for a real step forward? Eur J Cancer. 1996 Apr;32A(4):641–644. doi: 10.1016/0959-8049(95)00663-x. [DOI] [PubMed] [Google Scholar]
  29. Scheper R. J., Broxterman H. J., Scheffer G. L., Kaaijk P., Dalton W. S., van Heijningen T. H., van Kalken C. K., Slovak M. L., de Vries E. G., van der Valk P. Overexpression of a M(r) 110,000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance. Cancer Res. 1993 Apr 1;53(7):1475–1479. [PubMed] [Google Scholar]
  30. Sharp S. Y., Rogers P. M., Kelland L. R. Transport of cisplatin and bis-acetato-ammine-dichlorocyclohexylamine Platinum(IV) (JM216) in human ovarian carcinoma cell lines: identification of a plasma membrane protein associated with cisplatin resistance. Clin Cancer Res. 1995 Sep;1(9):981–989. [PubMed] [Google Scholar]
  31. Sharp S. Y., Rowlands M. G., Jarman M., Kelland L. R. Effects of a new antioestrogen, idoxifene, on cisplatin- and doxorubicin-sensitive and -resistant human ovarian carcinoma cell lines. Br J Cancer. 1994 Sep;70(3):409–414. doi: 10.1038/bjc.1994.319. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Stein U., Walther W., Laurencot C. M., Scheffer G. L., Scheper R. J., Shoemaker R. H. Tumor necrosis factor-alpha and expression of the multidrug resistance-associated genes LRP and MRP. J Natl Cancer Inst. 1997 Jun 4;89(11):807–813. doi: 10.1093/jnci/89.11.807. [DOI] [PubMed] [Google Scholar]
  33. Stratton M. R., Moss S., Warren W., Patterson H., Clark J., Fisher C., Fletcher C. D., Ball A., Thomas M., Gusterson B. A. Mutation of the p53 gene in human soft tissue sarcomas: association with abnormalities of the RB1 gene. Oncogene. 1990 Sep;5(9):1297–1301. [PubMed] [Google Scholar]
  34. Würl P., Taubert H., Bache M., Kroll J., Meye A., Berger D., Siermann A., Holzhausen H. J., Hinze R., Schmidt H. Frequent occurrence of p53 mutations in rhabdomyosarcoma and leiomyosarcoma, but not in fibrosarcoma and malignant neural tumors. Int J Cancer. 1996 Aug 22;69(4):317–323. doi: 10.1002/(SICI)1097-0215(19960822)69:4<317::AID-IJC14>3.0.CO;2-2. [DOI] [PubMed] [Google Scholar]
  35. Yanagisawa T., Newman A., Coley H., Renshaw J., Pinkerton C. R., Pritchard-Jones K. BIRICODAR (VX-710; Incel): an effective chemosensitizer in neuroblastoma. Br J Cancer. 1999 Jun;80(8):1190–1196. doi: 10.1038/sj.bjc.6990485. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES